NCT06292650 (MOON) is a EARLY_PHASE1 clinical trial of ZM-02-L in Retinitis Pigmentosa, sponsored by Zhongmou Therapeutics.

Who is sponsoring NCT06292650?

NCT06292650 is sponsored by Zhongmou Therapeutics.

What drugs are being tested in NCT06292650?

Interventions in NCT06292650: ZM-02-L, ZM-02-H, ZM-02-S.

What condition does NCT06292650 study?

NCT06292650 studies Retinitis Pigmentosa.

Is NCT06292650 still recruiting?

NCT06292650 is currently recruiting now. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT06292650: MOON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Recruiting now EARLY_PHASE1 Last updated 31 March 2026

What this trial tests

EARLY_PHASE1 trial testing ZM-02-L in Retinitis Pigmentosa in 12 participants. Currently enrolling.

Timeline

25 February 2024

Primary endpoint
25 December 2027

25 December 2028

Quick facts

Lead sponsor	Zhongmou Therapeutics
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	12
Start date	25 February 2024
Primary completion	25 December 2027
Estimated completion	25 December 2028
Sites	1 location across China

Drugs / interventions tested

ZM-02-L — full drug profile →
ZM-02-H — full drug profile →
ZM-02-S

Conditions studied

Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →

Sponsor

Zhongmou Therapeutics — full company profile →

Who can join

Adults 18 to 65, any sex, with Retinitis Pigmentosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Optogenetics and Targeted Gene Therapy for Retinal Diseases: Unravelling the Fundamentals, Applications, and Future Perspectives.
Kulbay M, Tuli N, Akdag A, Kahn Ali S, et al · · 2024 · cited 4× · PMID 39064263 · DOI 10.3390/jcm13144224
Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future Directions.
AlEissa MM, Alhawsawi AA, Alonazi R, Magharbil E, et al · · 2025 · cited 2× · PMID 40725503 · DOI 10.3390/genes16070847
Regulatory aspects of optogenetic research and therapy for retinitis pigmentosa under EU law.
Freise J. · · 2025 · cited 2× · PMID 40417352 · DOI 10.3389/fmedt.2025.1548927
Genetic engineering and the eye.
Murphy R, Martin KR. · · 2025 · cited 2× · PMID 39516652 · DOI 10.1038/s41433-024-03441-2

Verify or expand the search:

Other recruiting trials for Retinitis Pigmentosa

Currently open trials in the same condition.

NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting

Other Zhongmou Therapeutics trials

Trials by the same sponsor.

NCT07282457 — Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Th · Phase 1, PHASE2 · not yet recruiting
NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT06066008 — Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06292650 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongmou Therapeutics
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06292650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing